Safety, Efficacy, and Persistence of Long-Term Mirabegron Treatment for Overactive Bladder in the Daily Clinical Setting: Interim (1-Year) Report from a Japanese Post-Marketing Surveillance Study.

about

Persistence and adherence to overactive bladder medications in Japan: A large nationwide real-world analysis.Mirabegron improves quality-of-life, treatment satisfaction, and persistence in patients with overactive bladder: a multi-center, non-interventional, real-world, 12-month study.

P2860

Q38612038-772F6F9F-41BE-4CD3-97A2-378994BDC08D Q47563038-1F969D9F-0BC3-4B54-81FB-42612E810B38

P2860

Safety, Efficacy, and Persistence of Long-Term Mirabegron Treatment for Overactive Bladder in the Daily Clinical Setting: Interim (1-Year) Report from a Japanese Post-Marketing Surveillance Study.

Item

http://www.wikidata.org/entity/Q38649685

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Safety, Efficacy, and Persiste ...... -Marketing Surveillance Study.

@en

type

Item

label

Safety, Efficacy, and Persiste ...... -Marketing Surveillance Study.

@en

prefLabel

Safety, Efficacy, and Persiste ...... -Marketing Surveillance Study.

@en

P1476

Safety, Efficacy, and Persiste ...... -Marketing Surveillance Study.

@en

P2093

Daisuke Kato

http://www.w3.org/2001/XMLSchema#string

Hiromi Tabuchi

http://www.w3.org/2001/XMLSchema#string

Satoshi Uno

http://www.w3.org/2001/XMLSchema#string

P2860

Drug treatment patterns for the management of men with lower urinary tract symptoms associated with benign prostatic hyperplasia who have both storage and voiding symptoms: a study using the health improvement network UK primary care data.

Persistence and adherence with the new beta-3 receptor agonist, mirabegron, versus antimuscarinics in overactive bladder: Early experience in Canada

Impact on quality of life of urinary incontinence and overactive bladder: a systematic literature review.

Persistence and adherence in the treatment of overactive bladder syndrome with anticholinergic therapy: a systematic review of the literature.

Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability.

Long-term adherence to antimuscarinic therapy in everyday practice: a systematic review.

Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a β(3)-adrenoceptor agonist, in overactive bladder.

Efficacy and tolerability of mirabegron, a β(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial.

Persistence and Adherence with Mirabegron versus Antimuscarinic Agents in Patients with Overactive Bladder: A Retrospective Observational Study in UK Clinical Practice.

Mirabegron for the treatment of overactive bladder: a review of efficacy, safety and tolerability with a focus on male, elderly and antimuscarinic poor-responder populations, and patients with OAB in Asia.

P31

scholarly article

P356

10.1111/LUTS.12188

http://www.w3.org/2001/XMLSchema#string

P577

2017-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28762672

http://www.w3.org/2001/XMLSchema#string

Safety, Efficacy, and Persistence of Long-Term Mirabegron Treatment for Overactive Bladder in the Daily Clinical Setting: Interim (1-Year) Report from a Japanese Post-Marketing Surveillance Study.

about

P2860

P2860

Safety, Efficacy, and Persistence of Long-Term Mirabegron Treatment for Overactive Bladder in the Daily Clinical Setting: Interim (1-Year) Report from a Japanese Post-Marketing Surveillance Study.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P31

P356

P577

P698

P356

P1433

P1476

P2093

P2860

P31

P356

P577

P698